Mechanism of Action
CJC-1295 acts as a long-acting GHRH receptor agonist, stimulating GH secretion through the hypothalamic-pituitary axis.
DAC Technology and Albumin Binding
The Drug Affinity Complex on CJC-1295 reacts with circulating albumin via a Michael addition to form a stable covalent bond after subcutaneous injection. This creates an endogenous reservoir, albumin serves as a circulating depot, slowly releasing active CJC-1295 over days. Albumin's ~19-day half-life limits full duration to approximately 6-8 days for the peptide payload.[1]GHRH Receptor Activation
CJC-1295 binds GHRH receptors on pituitary somatotrophs, activating adenylyl cyclase via Gs protein coupling. This elevates intracellular cAMP, driving GH gene transcription and secretion. Unlike ghrelin/" class="wiki-internal-link">ghrelin receptor agonists (GHRPs), GHRH receptor activation specifically amplifies GH pulse amplitude without initiating new pulses.[1]Synergy with GHRPs
GHRH and GHRP act on different, complementary receptor systems. GHRH (via CJC-1295) primes somatotrophs and amplifies pulse amplitude; GHRPs (Ipamorelin, GHRP-2) initiate the pulsatile stimulus. The combination consistently produces GH pulses far exceeding either alone, a well-characterized pharmacological synergy.[2]Research Overview
GH and IGF-1 Elevation
Phase I/II ClinicalPhase I/II clinical trials in healthy adults demonstrated that a single CJC-1295 injection produces sustained GH elevation lasting 6+ days. Mean GH levels increased 2-10x above baseline for 6 days, with IGF-1 increases of 1.5-3x lasting 9-11 days after a single dose. Dose-proportional effects confirmed up to 30 mcg/kg.[1]
Body Composition and Recovery
Moderate EvidenceSustained IGF-1 elevation from CJC-1295 supports anabolic signaling, protein synthesis, and lipolysis. Preclinical models show improved body composition with chronic use. Human data is primarily from observational use in GH-deficient populations.[2]
Anti-aging Applications
EmergingGH and IGF-1 decline markedly with age, CJC-1295 protocols aim to restore younger GH/IGF-1 profiles. The once-weekly convenience distinguishes it from daily GHRH peptides. Data in healthy aging adults is limited but clinically evaluated.[1]
Calculate your CJC-1295 dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Clinical Trial Data
| Phase | Trial | N | Duration | Key Outcome |
|---|---|---|---|---|
| Phase 1 | Ionescu & Frohman PK study PMID:16822818 | 12 | Single dose | Half-life 5.8-8.1 days confirmed; GH AUC elevated for 7 days; IGF-1 elevated 14+ days post-injection |
| Phase 2 | Teichman et al. GH deficiency PMID:17636088 | 28 | 6 weeks | Once-weekly CJC-1295 restores GH pulsatility in GH-deficient adults; IGF-1 normalization in majority of subjects |
| Phase 1 | Safety PK study (multiple doses) PMID:15741266 | 21 | Multiple doses | Well-tolerated up to 60 mcg/kg; flushing most common AE; no cortisol or prolactin elevation |
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Stacked with Ipamorelin | 1 mg CJC-1295 + 200-300 µg Ipamorelin | 2× weekly (CJC) + daily (Ipa) | Subcutaneous |
| GH elevation baseline | 1 mg | Once weekly | Subcutaneous |
| Anti-aging protocol | 2 mg | Once weekly | Subcutaneous |
| Conservative start | 1 mg | Once weekly | Subcutaneous |
CJC-1295 (with DAC) can be injected at any time of day given its multi-day half-life, timing precision is less critical than for short-acting GHRPs. Most protocols pair once-weekly CJC-1295 with daily Ipamorelin for daily GH pulses on an elevated GHRH background. Note: CJC-1295 WITHOUT DAC (Mod GRF 1-29) has a ~30-min half-life and requires different dosing (100-300 mcg per injection, 2-3x daily, timed like Ipamorelin).
Research protocols only. Not medical advice.
Peptide Interactions
Safety Profile
CJC-1295 has been evaluated in human clinical trials and shows an acceptable safety profile at doses up to 30 mcg/kg.
WADA Status: Prohibited by WADA as a peptide hormone and growth factor. Athletes subject to testing must not use this compound.
Water retention: The most common reported effect, GH-driven sodium retention causes transient fluid retention. Usually mild and self-resolving.
Tunnel syndrome risk: Sustained supraphysiological GH/IGF-1 elevation has been associated with carpal tunnel syndrome in high-dose GH therapy. Monitor for tingling/numbness in hands with long protocols.
IGF-1 monitoring: Given the 9-11 day IGF-1 elevation per injection, monitoring IGF-1 levels quarterly is advisable for chronic users.
No FDA approval: Not approved for human therapeutic use.
References
- [1]Teichman SL, et al. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults." J Clin Endocrinol Metab. 2006;91(3):799-805. PMID:16352683
- [2]Ionescu M, Frohman LA. "Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog." J Clin Endocrinol Metab. 2006;91(12):4792-4797. PMID:17062766